Inhaled corticosteroids on mortality in COVID-19: A systematic review and meta-analysis of randomized controlled trials

Fen Yang; Guizuo Wang; Dong Han

doi:10.1177/10815589241249997

Inhaled corticosteroids on mortality in COVID-19: A systematic review and meta-analysis of randomized controlled trials

J Investig Med. 2024 May 15:10815589241249997. doi: 10.1177/10815589241249997. Online ahead of print.

Authors

Fen Yang¹, Guizuo Wang², Dong Han²

Affiliations

¹ Intensive Care Unit, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China.
² Department of Respiratory and Critical Care Medicine, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China.

PMID: 38747526
DOI: 10.1177/10815589241249997

Abstract

This systematic review and meta-analysis aimed to determine the efficacy of inhaled corticosteroids (ICS) on mortality in patients with coronavirus disease-2019 (COVID-19). A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on the treatment of COVID-19 with ICS were reviewed. Studies were pooled to risk ratios (RRs), with 95% confidence intervals (CIs). Eleven RCTs (enrolling 5832 participants) met the inclusion criteria. There was no statistically significant difference in COVID-19-related death (RR 0.88, 95% CI 0.38-2.04), all-cause death (RR 1.05, 95% CI 0.49-2.23), and invasive ventilation (RR 1.26, 95% CI 0.60-2.62) between the two groups. ICS was not associated with reduced mortality and invasive ventilation in patients with COVID-19.

Keywords: COVID-19; Mortality; inhaled corticosteroids; meta-analysis.

Publication types

Review